Literature DB >> 8200572

Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.

S Pearce1, H Thornes, D Carr, A Tanner.   

Abstract

A 50 year old man is described with hepatic dysfunction and chronic pancreatitis in whom greatly increased concentrations of the pancreatic tumour marker CA 19-9 combined with an abnormal appearance at endoscopic retrograde cholangiopancreatography lead to the false suspicion of pancreatic carcinoma. CA 19-9 concentrations should be interpreted with caution in patients with intrinsic liver disease or biliary obstruction.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8200572      PMCID： PMC1374763          DOI： 10.1136/gut.35.5.707

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  9 in total

1.  CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study.

Authors:  J Collazos; J Genolla; A Ruibal
Journal:  Clin Chim Acta       Date:  1992-09-15       Impact factor: 3.786

Review 2.  Hepatic clearance of serum glycoproteins.

Authors:  I G McFarlane
Journal:  Clin Sci (Lond)       Date:  1983-02       Impact factor: 6.124

3.  Pancreatic function testing: serum PABA measurement is a reliable and accurate measurement of exocrine function.

Authors:  A R Tanner; D P Robinson
Journal:  Gut       Date:  1988-12       Impact factor: 23.059

4.  Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases.

Authors:  D Basso; T Meggiato; C Fabris; M Plebani; P Fogar; M P Panozzo; G Del Favero
Journal:  Eur J Clin Invest       Date:  1992-12       Impact factor: 4.686

5.  Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank.

Authors:  R E Ritts; B C Del Villano; V L Go; R B Herberman; T L Klug; V R Zurawski
Journal:  Int J Cancer       Date:  1984-03-15       Impact factor: 7.396

6.  Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy.

Authors:  A DelMaschio; A Vanzulli; S Sironi; M Castrucci; R Mellone; C Staudacher; M Carlucci; A Zerbi; D Parolini; A Faravelli
Journal:  Radiology       Date:  1991-01       Impact factor: 11.105

7.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.

Authors:  D K Pleskow; H J Berger; J Gyves; E Allen; A McLean; D K Podolsky
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

Review 8.  Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA).

Authors:  P Thomas; N Zamcheck
Journal:  Dig Dis Sci       Date:  1983-03       Impact factor: 3.199

9.  CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.

Authors:  M Paganuzzi; M Onetto; P Marroni; D Barone; M Conio; H Aste; V Pugliese
Journal:  Cancer       Date:  1988-05-15       Impact factor: 6.860
  9 in total
  6 in total

1.  Biliary tract obstruction in chronic pancreatitis.

Authors:  Abdul A Abdallah; Jake E J Krige; Philippus C Bornman
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

2.  Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures.

Authors:  J C Saurin; M O Joly-Pharaboz; P Pernas; L Henry; T Ponchon; J J Madjar
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

3.  Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.

Authors:  Joo Kyung Park; Woo Hyun Paik; Ji Kon Ryu; Yong-Tae Kim; Youn Joo Kim; Jaihwan Kim; Byeong Jun Song; Jin Myung Park; Yong Bum Yoon
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

4.  Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer.

Authors:  Malcolm D Mattes; Jon S Cardinal; Geraldine M Jacobson
Journal:  Radiat Oncol J       Date:  2016-06-17

Review 5.  Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.

Authors:  Tsinrong Lee; Thomas Zheng Jie Teng; Vishal G Shelat
Journal:  World J Gastrointest Surg       Date:  2020-12-27

6.  A case of raised CA 19-9 in a patient with desmoplastic fibroblastoma of the upper limb.

Authors:  Kumaran Rasappan; Leanne Kayla Rebecca Mei-Yi Shaw; Lester Wai Mon Chan; Khoon Leong Chuah; Mathew Hern Wang Cheng
Journal:  Int Cancer Conf J       Date:  2021-04-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.